Astellas' oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine NHS use as a treatment for anaemia in chronic kidney disease (CKD), ahead of riv
Leela Barham takes a look at the latest milestone on what will have been a close to three-year journey to an Innovative Medicines Fund (IMF) in England.
Around 425,000 people in England and Wales with cardiovascular disease who are at risk of a secondary stroke or heart attack, could be eligible for treatment with Amarin's Vazkepa, followin
After a non-committal appraisal of Big Health's Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital thera
